Patents Examined by Khalid Masood
  • Patent number: 5874526
    Abstract: The present invention relates to peptides immunoreactive with antibodies to Toxoplasma gondii, nucleic acid sequences encoding these peptides, recombinant vector molecules, comprising these nucleic acid sequences, host cells transformed with the recombinant vector molecule, immunochemical reagents comprising the peptides or antibodies directed against the peptides, a test kit for the detection of T. gondii infections as well as a vaccine for the protection against T. gondii infections.In particular the present invention provides peptides comprising part of the amino acid sequence as shown in SEQ ID No.: 1.A preferred embodiment of the present invention are peptides comprising at least part of the amino acid sequence shown in SEQ ID No.: 3 or 5.It has been found that the peptides according to the present invention are particularly suitable for diagnosing T. gondii infected humans.
    Type: Grant
    Filed: October 6, 1995
    Date of Patent: February 23, 1999
    Assignee: Akzo Nobel N.V.
    Inventors: Marcus Joseph Marie Koolen, Johannes Jozef Wilhelmus De Haard
  • Patent number: 5874633
    Abstract: A concentrated single phase aqueous alkaline solution of tetrahydroiso-.alpha.-acids having greater than 10% to about 45% w/w tetrahydroiso-.alpha.-acids is disclosed. A method of hydrogenating and formulating a starting solution of iso-.alpha.-acids to obtain such concentrated solutions of tetrahydroiso-.alpha.-acids is also disclosed.
    Type: Grant
    Filed: October 30, 1996
    Date of Patent: February 23, 1999
    Assignee: Miller Brewing Company
    Inventors: Patrick L. Ting, Henry Goldstein
  • Patent number: 5871738
    Abstract: Disclosed is a substantially purified antigen derived from a first parasitic nematode species which, when administered to a host animal, is capable of protecting the host animal from infestation by a second parasitic nematode species, wherein the first and second parasitic nematode species may be the same or different, and the antigen has an apparent molecular weight of 40 kD as determined by SDS-PAGE under reducing conditions.
    Type: Grant
    Filed: October 6, 1992
    Date of Patent: February 16, 1999
    Assignees: Biotech Australia Pty. Limited, Commonwealth Scientific and Industrial Research Organization
    Inventors: Phillip John Sharp, Barry Maxwell Wagland
  • Patent number: 5869263
    Abstract: Disclosed is a substantially pure antibody which specifically binds a LCF polypeptide and methods of using such antibodies.
    Type: Grant
    Filed: December 29, 1995
    Date of Patent: February 9, 1999
    Assignee: Research Corporation Technologies, Inc.
    Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
  • Patent number: 5864014
    Abstract: A membrane-associate protein which is present on the surface of, inter alia, intestinal epithelia cells, is disclosed. The protein acts as a receptor for the zonula occludens toxin of Vibrio cholera, and is related to the modulation of intestinal tight junctions. Also disclosed are methods for the use of the same to screen for analogs of Vibrio cholera zonula occludens toxin.
    Type: Grant
    Filed: February 20, 1997
    Date of Patent: January 26, 1999
    Assignee: University of Maryland at Baltimore
    Inventor: Alessio Fasano
  • Patent number: 5854020
    Abstract: Novel response regulator polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polynucleotides and polypeptides for the treatment of infection, particularly bacterial infections. Antagonists against such the polypeptides of the invention and their use as a therapeutic to treat infections, particularly bacterial infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence the nucleic acid sequences and the polypeptides of the invention in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding response regulators and for detecting the polypeptide in a host.
    Type: Grant
    Filed: December 20, 1996
    Date of Patent: December 29, 1998
    Assignee: SmithKline Beecham p.l.c.
    Inventors: John Edward Hodgson, Nicola Gail Wallis
  • Patent number: 5843710
    Abstract: Disclosed is the invention relates to proteins derived from parasitic nematodes which confer protective immunity against infection by parasitic nematodes, to nucleotide sequences encoding these proteins, to recombinant molecules containing such sequences to host cells transformed with such recombinant molecules and methods for the production of the nucleotide sequences recombinant molecules and hosts. The invention also relates to vaccines comprising proteins of the invention together with suitable carriers or diluents and to antibodies raised against proteins of the invention.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 1, 1998
    Assignee: Biotech Australia Pty. Limited and Csiro
    Inventors: Gary Stewart Cobon, Rosemary Ann Austen, Ian Joseph O'Donnell, Maurice Joseph Frenkel, William Peter Keith Kennedy, Keith William Savin, Barry Maxwell Wagland
  • Patent number: 5843706
    Abstract: The invention disclosed relates to proteins derived from parasitic nematodes that confer protective immunity against infection by parasitic nematodes, to nucleotide sequences encoding those proteins, to recombinant molecules containing such sequences, to host cells transformed with such recombinant molecules and methods for the production of the nucleotide sequences, recombinant molecules and hosts. The invention also relates to vaccines comprising proteins of the invention together with suitable carriers or diluents and to antibodies raised against proteins of the invention.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 1, 1998
    Assignees: Biotechnology Australia Pty, Ltd., Commonwealth Scientific and Industrial Organization
    Inventors: Gary Stewart Cobon, Rosemary Ann Austen, Ian Joseph O'Donnell, Maurice Joseph Frenkel, William Peter Keith Kennedy, Keith William Savin, Barry Maxwell Wagland
  • Patent number: 5837269
    Abstract: The invention relates to a vaccine which comprises an antigen and an immune response augmenting agent. The immune response augmenting agent is capable of enhancing T cell lymphokine production. Suitable immune response augmenting agents include, but are not limited to, DHEA, DHEA-derivatives and DHEA congeners.The invention also relates to a method for enhancing a vaccine-induced humoral immune response which comprises administering a vaccine which comprises an antigen and an immunomodulator. The immunomodulator may be an immune response augmenting agent, a lymphoid organ modifying agent or a mixture of the immune response augmenting agent and lymphoid organ modifying agent. Suitable lymphoid organ modifying agents include, but are not limited to, 1,25-dihydroxy Vitamin D.sub.3, 25-hydroxy Vitamin D.sub.3, biologically active 1,25-dihydroxy Vitamin D.sub.3, derivatives which are capable of activating the intra-cellular Vitamin D.sub.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 17, 1998
    Assignee: University of Utah Research Foundation
    Inventors: Raymond A. Daynes, Barbara A. Araneo
  • Patent number: 5834027
    Abstract: A method of treating animals, particularly rhea and ostrich chicks with adipose depletion, by injection with an oil derived from rhea or ostrich adipose or by injection with an active component of the oil that increases anti-inflammatory capabilities and phospholipid formation.
    Type: Grant
    Filed: April 3, 1996
    Date of Patent: November 10, 1998
    Inventor: Donna L. Cardinale Fezler
  • Patent number: 5830993
    Abstract: New antimicrobial truncated peptides are disclosed which are based upon a known peptide, PR-39 (SEQ ID NO: 1) but which contain a lesser number of amino acid residues yet still retain antimicrobial activity. The most preferred peptide compound is PR-26, SEQ ID NO: 2. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention.
    Type: Grant
    Filed: April 10, 1995
    Date of Patent: November 3, 1998
    Assignee: Kansas State University Research Foundation
    Inventors: Frank Blecha, Jishu Shi
  • Patent number: 5831012
    Abstract: Novel proteins obtainable by mutagenesis of surface-exposed amino acids of domains of natural bacterial receptors, said proteins being obtained without substantial loss of basic structure and stability of said natural bacterial receptors; proteins which have been selected from a protein library embodying a repertoire of said novel proteins; and methods for the manufacture of artificial bacterial receptor structures.
    Type: Grant
    Filed: August 15, 1996
    Date of Patent: November 3, 1998
    Assignee: Pharmacia & Upjohn Aktiebolag
    Inventors: Bjorn Nilsson, Per-.ANG.ke Nygren, Mathias Uhlen
  • Patent number: 5827718
    Abstract: Bacteria belonging to the genus Pseudomonas, alkaline lipase produced by the bacteria and having the following properties, a method of producing the lipase, and detergent compositions containing the lipase:(1) Operating pH and optimum pHan operating pH is in the range of from 3.5 to 12 and an optimum pH is in the range of from 10 to 11 using a triolein emulsion as a substrate;(2) Operating temperature and optimum temperaturean operating temperature is in the range of from 30.degree. C. to 80.degree. C. and an optimum temperature is in the range of from 55.degree. C. to 65.degree. C. using the triolein emulsion as a substrate;(3) Molecular weighta molecular weight measured by SDS-polyacrylamide gel electrophoresis is 31,000.+-.2,000; and(4) Isoelectric pointan Isoelectric point measured by isoelectric point polyacrylamide gel electrophoresis is 5.2.+-.0.5.The lipase has high stability against detergent components such as surfactants, protease, etc. and can be blended together with protease with detergents.
    Type: Grant
    Filed: March 14, 1996
    Date of Patent: October 27, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Reiko Ishida, Masahiro Suzuki, Takashi Kotsuka, Kazunori Sakimoto
  • Patent number: 5821335
    Abstract: The invention provides isolated nucleic acid compounds encoding the stem peptide biosynthetic gene murG of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the MurG enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.
    Type: Grant
    Filed: November 19, 1996
    Date of Patent: October 13, 1998
    Assignee: Eli Lilly and Company
    Inventors: Jo Ann Hoskins, Paul Luther Skatrud, Robert Brown Peery
  • Patent number: 5808009
    Abstract: The present invention relates to a method of affinity purifying antibodies consisting of the following steps: A) homogenizing Helminth parasite worms forming a mixture; B) incubating the mixture of adult Helminth parasite worm homogenate with pre-swelled CNBr-activated Sepharose 4B in coupling buffer; C) first washing the mixture with blocking buffer; D) second washing the mixture with acetate buffer and coupling buffer; E) third washing the mixture with Phosphate Buffered Solution; F) pouring the mixture into a chromatography column; G) allowing the mixture to settle; H) first passing, by gravity, a solution of saturated ammonium sulfate precipitated antibodies in loading buffer through the chromatography column; I) second passing, by gravity, loading buffer through the chromatography column until thoroughly washed; and J) second passing, by gravity, chromatography column elution buffer through the chromatography column which functions to remove and the purified antibodies.
    Type: Grant
    Filed: September 23, 1996
    Date of Patent: September 15, 1998
    Assignee: North Dakota State University Research Foundation
    Inventors: Michael Robinson, Thomas Russell Gustad, Steven Wayne Meinhardt
  • Patent number: 5798106
    Abstract: This invention relates to a novel protein capable of inducing an immune response protective against human malarial infection caused by Plasmodium falciparum, and to the cloning and expression of a gene encoding the said protein. The invention further relates to novel vaccines comprising the said protein and to their use in the vaccination of humans at risk from malaria.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: August 25, 1998
    Assignee: University of Nijmegan
    Inventors: Johannes Gerardus Ghislain Schoenmakers, Rudolph Nicholaas Hendrik Konings, Inge Irma Maria Dominique Moelans
  • Patent number: 5788985
    Abstract: The invention provides novel uses for n-glycolylated gangliosides, or derivatives and/or oligosaccharides thereof. The invention further provides methods of obtaining such gangliosides, as well as vaccine compositions comprising said gangliosides. The gangliosides may be coupled to carriers and may be accompanied by adjuvants. The vaccine compositions can be used in the treatment of breast cancers, whereby the gangliosides are used to elicit an immune response to corresponding gangliosides on breast tumour cells.
    Type: Grant
    Filed: December 29, 1994
    Date of Patent: August 4, 1998
    Assignee: Centro de Inmunologia Molecular
    Inventors: Rolando Perez Rodriguez, Luis Enrique Fernandez Molina, Gilda Marquina Rodriguez, Adriana Carr Perez, Oscar Gonzalo Valiente Hernandez
  • Patent number: 5789549
    Abstract: The present invention relates to new recombinant DNA-molecules comprising nucleotide sequences of S. dysgalactiae encoding for at least one protein or polypeptide having fibronectin binding property.
    Type: Grant
    Filed: October 7, 1996
    Date of Patent: August 4, 1998
    Assignee: Alfa Laval Agri International Aktiebolag
    Inventors: Magnus Hook, Kjell Martin Lindberg, Per-Eric Lindgren, Lars Christer Signas
  • Patent number: 5789194
    Abstract: The present invention relates to parasitic helminth venom allergen antigen 5-like proteins; to parasitic helminth venom allergen antigen 5-like nucleic acid molecules, including those that encode such proteins; and to antibodies raised against such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules and antibodies. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules and/or antibodies, as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic helminths.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: August 4, 1998
    Assignee: Heska Corporation
    Inventors: Cynthia Ann Tripp, Nancy Wisnewski
  • Patent number: 5780261
    Abstract: The invention provides a method and expression system for enhancing secretion of hyperproduced homologous and heterologous exoproteins in gram-positive bacteria such as Bacillus sp. The method and system comprise overproduction of PrsA protein in gram-positive bacterial host capable of also overproducing at least one exoprotein of interest. Use of the method and system of the invention results in greatly enhanced secretion of the synthesized exoproteins into the growth medium. Once in the growth medium these secreted exoproteins can be recovered and purified in a straightforward manner.
    Type: Grant
    Filed: July 8, 1996
    Date of Patent: July 14, 1998
    Assignee: The Finnish National Public Health Institute (KTL)
    Inventors: Vesa Kontinen, Matti Sarvas